BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16141295)

  • 1. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
    Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
    Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
    Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
    Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
    Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
    Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
    Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
    Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
    Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
    Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
    Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Azuma M; Shimoda T; Nishimura K; Nakatani K; Saigenji K
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1957-61. PubMed ID: 15570920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
    Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
    Koizumi W; Tanabe S; Saigenji K; Ohtsu A; Boku N; Nagashima F; Shirao K; Matsumura Y; Gotoh M
    Br J Cancer; 2003 Dec; 89(12):2207-12. PubMed ID: 14676796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
    Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
    Sato Y; Kondo H; Honda K; Takahari D; Sumiyoshi T; Tsuji Y; Yoshizaki N; Niitsu Y
    Int J Clin Oncol; 2005 Feb; 10(1):40-4. PubMed ID: 15729600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
    Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
    Komatsu Y; Yuki S; Miyagishima T; Asaka M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():75-8. PubMed ID: 16897976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.